Today: 20 May 2026
Browse Category

LSE:GSK 28 December 2025 - 28 January 2026

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 fell 0.3% to 10,177.85 as a stronger pound hit overseas earners. Gold reached a record above $5,300 an ounce, boosting miners, while Marston’s dropped up to 16% on flat 17-week sales. Traders awaited the U.S. Fed’s policy decision later Wednesday. Oil prices eased but held near four-month highs after U.S. supply disruptions.
28 January 2026
········
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK shares dropped 1.8% to 1,828.5 pence by mid-morning Wednesday in London, reversing gains from earlier in the week. The decline followed news that the European Commission expanded approval of GSK’s RSV vaccine Arexvy to all adults 18 and older. Pfizer also secured similar approval for its RSV shot. Investors await guidance from European health agencies and GSK’s earnings report on February 4.
28 January 2026
···
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
24 January 2026
·····
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···
GSK share price slips into the weekend as investors brace for Feb. 4 results

GSK share price slips into the weekend as investors brace for Feb. 4 results

GSK shares fell 1.7% to 1,816.5 pence in London Friday, with trading volume above recent averages. Senior executives disclosed routine share purchases via dividend reinvestment. Investors now await GSK’s fourth-quarter results on Feb. 4 and the upcoming dividend timetable. Debate continues over U.S. fast-track drug approvals, with GSK linked to the FDA’s voucher program.
18 January 2026
··
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK shares fell 1.7% to 1,817 pence in London Friday, extending a three-day slide and closing 11.7% below their December peak. Trading volume surged to 12.6 million shares. Filings showed senior executives reinvested dividends into shares and U.S. ADSs. Investors are awaiting GSK’s full-year results and U.S. drug-approval updates in early February.
17 January 2026
·····
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
14 January 2026
···
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK said its hepatitis B drug bepirovirsen met primary endpoints in two phase III trials, with global filings planned from early 2026. Shares closed up 4.3% after the news. The European Commission approved a new syringe format for Shingrix, and Japan cleared Exdensur for severe asthma. Investors await full phase III data on bepirovirsen’s durability and safety before sales impact is clear.
7 January 2026
··
London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

The FTSE 100 closed at 9,870.68 in a muted, low-volume session ahead of the Christmas break, down about 0.2%. Despite the quiet finish, the index is up 20.7% for 2025, on track for a fifth consecutive yearly gain. U.S. markets ended Friday nearly flat, while gold and silver hit new records. London trading resumes Monday amid thin liquidity and strong commodity moves.
28 December 2025
···
1 2 3 4

Stock Market Today

  • Stocks Added to Zacks Strong Sell List on May 20th: BRCC, CVE, MITT
    May 20, 2026, 5:27 AM EDT. Three stocks joined the Zacks Rank #5 (Strong Sell) list on May 20th. BRC Inc. (BRCC), a coffee and apparel seller, saw its current year earnings estimate cut by 33.3%. Cenovus Energy Inc. (CVE), an oil and gas producer, had its earnings forecast lowered by 24.5%. AG Mortgage Investment Trust (MITT), a residential mortgage REIT, faced a 17.5% earnings revision downward. These revisions reflect growing bearish sentiment as analysts adjust expectations. The Zacks Rank #5 indicates a strong sell recommendation based on recent downward earnings revisions over 60 days.

Latest articles

Intel’s AI Comeback Just Got a $150 Wall Street Test

Intel’s AI Comeback Just Got a $150 Wall Street Test

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
Marvell shares active as earnings approach, AI chip focus in view

Marvell shares active as earnings approach, AI chip focus in view

20 May 2026
Marvell Technology shares rose 4.53% to $184.25 in premarket trading Wednesday, extending Tuesday’s 4.35% gain. The company will report fiscal Q1 2027 results after the close on May 27. Analysts at Evercore ISI, Melius Research, and CLSA raised price targets, citing strong demand for custom AI chips. Marvell posted record fiscal 2026 revenue of $8.195 billion in March.
SpaceX restarts Starlink launches after satellite mishap — and another Falcon 9 is already queued

SpaceX IPO Moves Closer as Goldman Nears Top Role in $1.75 Trillion Listing

20 May 2026
Goldman Sachs is set to lead SpaceX’s planned IPO, which could become the largest in history, with a targeted valuation of about $1.75 trillion, Reuters reported. SpaceX aims to publish its prospectus as soon as Wednesday and list on Nasdaq under the ticker SPCX as early as June 12. The company’s next Starship test flight is scheduled for May 21 from Texas. Morgan Stanley, Bank of America, Citigroup, and JPMorgan are also expected to play major roles.
Go toTop